Install
- 1,289articles · 30d
- 4+ hour agolatest article
- Aug 17, 2026earliest in window
- 0%with images
- 222avg words
- Science & Nature 900
- Science & Technology 854
- STEM 553
- Health & Wellness 396
- Medical 310
- Health 193
- Environment 163
- Computers & Electronics 69
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Eight-year ADAURA update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated NSCLC
6+ hour, 38+ min ago (140+ words) Exploratory analysis reports the longest overall survival follow-up from a global Phase III adjuvant trial in EGFR-mutated NSCLC image: Roy Herbst, M.D., Phd, of Dartmouth Cancer Center, Lebanon, N.H. view more Credit: Roy Herbst, M.D., Phd, of Dartmouth Cancer Center, Lebanon, N.H. The study…...
Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. [IMAGE] | EurekAlert! Science News Releases
1+ day, 3+ hour ago (74+ words) dijo la profesora Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. EurekAlert! Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer…...
Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China.
1+ day, 5+ hour ago (72+ words) EurekAlert! Professor Jie Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing, China. More on this News Release Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves…...
Professor Li Zhang of Sun Yat-sen University Cancer Center, Guangzhou, China
1+ day, 1+ hour ago (43+ words) (IMAGE) EurekAlert! Professor Li Zhang of Sun Yat-sen University Cancer Center, Guangzhou, China More on this News Release Phase III TAISHAN-302 trial shows Tam-Peli significantly improves survival in relapsed small-cell lung cancer...
Chad Rusthoven, MD, of the University of Colorado School of Medicine [IMAGE] | EurekAlert! Science News Releases
1+ day, 3+ hour ago (46+ words) Chad Rusthoven, MD, of the University of Colorado School of Medicine (IMAGE) EurekAlert! Chad Rusthoven, MD, of the University of Colorado School of Medicine More on this News Release Phase III MAVERICK trial supports brain MRI surveillance alone as standard…...
Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer
1+ day, 5+ hour ago (137+ words) B7-H3-directed antibody-drug conjugate reduced the risk of death by 54% compared with topotecan and improved progression-free survival and response rates At the June 6, 2026 data cutoff, after a median follow-up of 12.2 months, median overall survival was 18.5 months with Ris-Rez compared with 10.3 months…...
Prof. Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
1+ day, 3+ hour ago (47+ words) EurekAlert! Prof. Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. More on this News Release Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC...
Giannis Mountzios, M.D., of the Henry Dunant Hospital Center, Athens, Greece [IMAGE] | EurekAlert! Science News Releases
1+ day, 1+ hour ago (43+ words) Giannis Mountzios, M.D., of the Henry Dunant Hospital Center, Athens, Greece (IMAGE) EurekAlert! Giannis Mountzios, M.D., of the Henry Dunant Hospital Center, Athens, Greece More on this News Release Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high…...
Protein linked to cell death may also drive liver cancer
3+ day, 10+ hour ago (295+ words) Discovery could open new approach to liver cancer treatment image: University of Oklahoma College of Medicine researcher Deepa Sathyaseelan, Ph.D., is the senior author of a new study in Hepatology that sheds light on a protein linked to liver cancer....
Rare Coombs-negative hemolytic anemia reported following pembrolizumab treatment
3+ day, 10+ hour ago (189+ words) image: Oncoscience is a peer-reviewed, open-access, traditional journal covering the rapidly growing field of cancer research, especially emergent topics not currently covered by other journals. This journal has a special mission: freeing oncology from publication costs. It is free to…...